Bausch Health Companies Inc.
Bausch Health Companies Inc. (BHC): 300 pipeline candidates · 18 upcoming catalysts · ~8 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.9 months
D/E -12.42 · 0% dilution
N/A
300 candidates
18 upcoming, next in ~167d
0 buys · 4 sells (180d)
A transparent, data-derived signal for Bausch Health Companies Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.9B
Cash
$1.3B
Quarterly Burn
$1.0B
Runway
7.9 mo
Revenue
$2.5B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (300 candidates)
Showing 10 of 300 candidates. Sign up for full pipeline.
Upcoming Catalysts (18)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
228
Total value held
$854.9M
| Holder | Shares | Value |
|---|---|---|
| goldentree asset management lp | 34,665,731 | $187.0M |
| vanguard capital management llc | 14,807,518 | $80.0M |
| royal bank of canada | 11,363,498 | $61.4M |
| nomura holdings inc | 8,986,372 | $48.5M |
| healthcare of ontario pension plan trust fund | 8,000,000 | $43.2M |
| geode capital management, llc | 4,228,871 | $31.4M |
| goldman sachs group inc | 5,207,966 | $28.1M |
| hudson bay capital management lp | 5,000,000 | $27.0M |
| ing groep nv | 5,000,000 | $27.0M |
| nuveen, llc | 3,798,957 | $20.5M |
Showing top 10 of 228 institutional holders of Bausch Health Companies Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Bausch Health Companies Inc.'s pipeline?
Bausch Health Companies Inc. (BHC) has 300 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bausch Health Companies Inc.'s lead drug candidate?
Bausch Health Companies Inc.'s most advanced tracked candidate is 14-day fecal molecular susceptibility-guided therapy (Phase 4) for HELICOBACTER PYLORI INFECTIONS; Helicobacter Pylori Infection.
What is Bausch Health Companies Inc.'s next catalyst?
Bausch Health Companies Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: CLINDESSE" — expected December 2, 2026.
What is Bausch Health Companies Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Bausch Health Companies Inc. has approximately 7.9 months of cash runway.
What is Bausch Health Companies Inc.'s market capitalization?
Bausch Health Companies Inc.'s market capitalization is approximately $1.9B.
Get the full picture on Bausch Health Companies Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.